changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
28 April 2018
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.
17 May 2016
BTG, the technology healthcare company that develops products to shrink liver tumours and zap blood clots, has enjoyed a “coming of age”, its boss has said, after revealing that profits more than doubled last year.
5 April 2016
BTG plc (LSE: BTG), a global specialist healthcare company, has today announced the publication of a new medtech innovation briefing (MIB) by NICE (National Institute for Health and Care Excellence) for TheraSphere yttrium-90 glass microsphere therapy.1
30 March 2016
Imagine an exquisitely precise cancer therapy procedure done through a small opening in the body
29 September 2015
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received additional approval for the vascular embolization device DC Bead® (specially controlled medical device, “DC Bead”) to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan.
5 September 2015
BILLINGS – Millions of tiny glass beads have given some liver cancer patients in Billings another option in their fight against the disease.